Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Spreen

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
The Lancet. HIV|May 27, 2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialMartin Markowitz, Ian Frank, Robert M Grant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic FailureChloe Orkin, Jonathan M Schapiro, Carlo F Perno, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
Plos Medicine|November 9, 2018
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J Landovitz, Sue Li, Beatriz Grinsztejn, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionChloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
The Lancet. HIV|May 27, 2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialMartin Markowitz, Ian Frank, Robert M Grant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic FailureChloe Orkin, Jonathan M Schapiro, Carlo F Perno, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
Plos Medicine|November 9, 2018
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J Landovitz, Sue Li, Beatriz Grinsztejn, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionChloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.
Pageof 5